Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

Table 1 Comparison of body weight and serum data between deferasirox and control groups

	Body weight	TP	Albumin	T-bil	AST	ALTa	ALP	BUN	CRE
	(g)	(g/dL)	(g/dL)	(mg/dL)	(IU/L)	(IU/L)	(IU/L)	(mg/dL)	(mg/dL)
Control	40.7 ± 4.1	5.6 ± 0.4	2.8 ± 0.2	0.5 ± 0.1	95.8 ± 33.9	92.3 ± 43.1	175.1 ± 23.2	25.5 ± 2.9	0.4 ± 0.1
DFX	42.8 ± 4.7	5.2 ± 0.5	2.7 ± 0.1	0.6 ± 0.3	87.6 ± 20.1	29.5 ± 13.8	162.2 ± 35.9	30.2 ± 1.6	0.6 ± 0.1

Mean ± SD.

^aP < 0.05. DFX: Deferasirox; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; BUN: Blood urea nitrogen; TP: Total protein; CRE: Creatinine.